This breakfast symposium will focus on the role of molecular testing in diagnosing myelodysplastic syndromes (MDS) and targeting treatment; the latest therapy options for low-risk and high-risk MDS patients; and disease management strategies to address quality of life issues and treatment adherence. Case studies will be used to illustrate the clinical value of molecular testing for MDS, best supportive care options, and care planning.
This symposium is supported by an independent medical education grant from Celgene Corporation
